Published : Aug-2017
No. of Pages : 204
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Introduction 12
2.1 Contact Lenses Overview 12
3 Products under Development 13
3.1 Contact Lenses - Pipeline Products by Stage of Development 13
3.2 Contact Lenses - Pipeline Products by Segment 14
3.3 Contact Lenses - Pipeline Products by Territory 15
3.4 Contact Lenses - Pipeline Products by Regulatory Path 16
3.5 Contact Lenses - Pipeline Products by Estimated Approval Date 17
3.6 Contact Lenses - Ongoing Clinical Trials 18
4 Contact Lenses - Pipeline Products under Development by Companies 19
4.1 Contact Lenses Companies - Pipeline Products by Stage of Development 19
4.2 Contact Lenses - Pipeline Products by Stage of Development 21
5 Contact Lenses Companies and Product Overview 23
5.1 Aeon Astron Corporation Company Overview 23
5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Alcon Laboratories Inc Company Overview 25
5.2.1 Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.3 Apeliotus Ophthalmics (Inactive) Company Overview 33
5.3.1 Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33
5.4 Auburn University Company Overview 35
5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview 35
5.5 Axcelon Biopolymers Corp. Company Overview 36
5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 36
5.6 Bar-Ilan University Company Overview 37
5.6.1 Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 37
5.7 Bausch & Lomb Inc Company Overview 38
5.7.1 Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 38
5.8 Children's Hospital Boston Company Overview 42
5.8.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
5.9 CooperVision Inc Company Overview 43
5.9.1 CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.10 EP Global Communications, Inc. Company Overview 48
5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
5.11 Euclid Systems Corp Company Overview 49
5.11.1 Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 e-Vision Medical Devices, Inc. Company Overview 50
5.12.1 e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
5.13 Eyenovations Company Overview 51
5.13.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 51
5.14 EyeYon Medical Company Overview 52
5.14.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 52
5.15 Imperial College London Company Overview 53
5.15.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 53
5.16 Johnson & Johnson Vision Care Inc Company Overview 54
5.16.1 Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 54
5.17 Massachusetts Eye and Ear Infirmary Company Overview 56
5.17.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 56
5.18 Novartis AG Company Overview 57
5.18.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 57
5.19 Ocular Dynamics, LLC Company Overview 58
5.19.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
5.20 Ocutec Ltd Company Overview 59
5.20.1 Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
5.21 Presbia Plc Company Overview 60
5.21.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 60
5.22 RetMap Inc Company Overview 63
5.22.1 RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.23 Stanford University Company Overview 64
5.23.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 64
5.24 SynergEyes Inc Company Overview 65
5.24.1 SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview 65
5.25 The Hong Kong University of Science and Technology Company Overview 67
5.25.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 67
5.26 The University of New South Wales Company Overview 68
5.26.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 68
5.27 UltraVision CLPL Company Overview 69
5.27.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 University of California San Diego Company Overview 70
5.28.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 70
5.29 University of Florida Company Overview 72
5.29.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 72
5.30 University of Valencia Company Overview 73
5.30.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 73
5.31 University of Washington Company Overview 75
5.31.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 75
5.32 Valeant Pharmaceuticals International Inc Company Overview 77
5.32.1 Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 77
5.33 Visioneering Technologies Inc Company Overview 90
5.33.1 Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90
5.34 VISTAKON Pharmaceuticals LLC Company Overview 94
5.34.1 VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 94
5.35 Yolia Health Company Overview 95
5.35.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 95
6 Contact Lenses- Recent Developments 96
6.1 Jul 13, 2017: Visioneering Technologies Appoints Michelle Kirst as Territory Manager for New Jersey 96
6.2 Jul 11, 2017: Visioneering Technologies Appoints Ron Makelke as Territory Manager for San Francisco 96
6.3 Jul 06, 2017: Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX Contact Lenses 97
6.4 Jul 06, 2017: Visioneering Technologies Appoints Carol Baez as Executive Territory Manager for Orange County/San Diego 97
6.5 Jun 29, 2017: Visioneering Technologies Announces Connie Stewart as Territory Manager, Los Angeles 98
6.6 Jun 27, 2017: Visioneering Technologies Names Mark Rapoport as New CFO 98
6.7 Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International 99
6.8 Jun 20, 2017: Visioneering Technologies Announces Dave Halverson as Territory Manager in Southern California 99
6.9 Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 100
6.10 Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 100
6.11 Jun 13, 2017: KAMRA Corneal Inlay Helps College Administrator End Her Blurry Near Vision and Dependence on Reading Glasses 100
6.12 Jun 10, 2017: Three-Year Study Indicates Pioneering Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% 101
6.13 Jun 10, 2017: Three-year study says new contact lens therapy slows myopia progression in children by 59 percent 102
6.14 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 103
6.15 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 104
6.16 May 30, 2017: The German Court has Granted a Preliminary Injunction in Favour of VSY Biotechnology BV and Against Carl Zeiss Meditec 105
6.17 May 23, 2017: Presbia Provides Update on US Staged Pivotal Clinical Trial For Flexivue Microlens 106
6.18 May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution 106
6.19 May 11, 2017: Hoya Reports Fourth Quarter and Full-Year Financial Results 107
6.20 May 10, 2017: Carl Zeiss Meditec accelerates growth in the first six months of 2016/17 108
6.21 May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 109
6.22 May 08, 2017: ZEISS Appoints New Fellow 109
6.23 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 110
6.24 May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 111
6.25 May 03, 2017: Presbia to Participate in the 2017 ASCRS Symposium & Congress in Los Angeles, California 112
6.26 May 02, 2017: KAMRA Corneal Inlay Utilizes Camera Technology to Sharpen and Clear Blurry Near Vision for Patients 112
6.27 May 01, 2017: Visioneering Technologies Expands US Sales Force 113
6.28 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 113
6.29 Apr 25, 2017: Essilor International: Revenue increases by 10% Q1 in line with planned 2017 growth trajectory 117
6.30 Apr 04, 2017: Carl Zeiss Meditec Group achieves first half 2016/17 revenue of approximately EUR 588 million 120
6.31 Mar 30, 2017: Bausch + Lomb ULTRA For Astigmatism Contact Lenses Introduced 120
6.32 Mar 27, 2017: Visioneering Technologies Successfully Lists on ASX 121
6.33 Mar 15, 2017: Bausch + Lomb Introduces Biotrue ONEday For Astigmatism Contact Lenses 122
6.34 Mar 08, 2017: The KAMRA Corneal Inlay Brings Life Back into Focus for Patients with Presbyopia, Blurring Near Vision 122
6.35 Mar 03, 2017: Visioneering Technologies Announces Launch of NaturalVue Sphere 1 Day Contact Lenses 123
6.36 Mar 02, 2017: Johnson & Johnson Vision Expands Portfolio to Reach More Patients with ACUVUE OASYS 1-DAY Brand Contact Lenses for ASTIGMATISM 124
6.37 Mar 02, 2017: The Cooper Companies Announces First Quarter Results 124
6.38 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 125
6.39 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 129
6.40 Feb 17, 2017: Essilor International Reports 2016 Financial Results 130
6.41 Feb 10, 2017: Carl Zeiss Meditec Off to A Solid Start Into Business Year 2016/17 137
6.42 Jan 31, 2017: Hoya Announces Third Quarter Financial Results 138
6.43 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 138
6.44 Jan 26, 2017: Achievement of sales milestone for COPD products 139
6.45 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 140
6.46 Jan 24, 2017: Visioneering Technologies Announces Pam Wyman as Director, Sales Operations & Inside Sales 147
6.47 Jan 18, 2017: Bausch + Lomb Introduces Zen RC Scleral Contact Lenses 147
6.48 Jan 17, 2017: Visioneering Technologies Announces Jeff Babbe as New Executive Territory Manager for Chicago, IL 148
6.49 Jan 11, 2017: Paragon CRT Contact Lenses Approved by China Food & Drug Administration 148
6.50 Jan 10, 2017: Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA For Presbyopia Contact Lenses 149
6.51 Jan 10, 2017: Bausch + Lomb ULTRA for Presbyopia Contact Lenses Parameters Expanded 150
6.52 Jan 10, 2017: Stephen Petranek Appointed to NexOptic Board 150
6.53 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 151
6.54 Jan 04, 2017: First Contact Lenses Specifically Designed for Digital Lifestyles Makes their CES Debut 152
6.55 Dec 21, 2016: Visioneering Technologies Announces Brian Atkinson as Territory Manager for the Dallas/Ft. Worth Market 153
6.56 Dec 13, 2016: Visioneering Technologies Announces Ken Gold as New Executive Territory Manager for the Baltimore-Washington, DC Area 153
6.57 Dec 12, 2016: Bausch + Lomb Specialty Vision Products Launches New 28 Lens Zenlens Dx Set 154
6.58 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 154
6.59 Dec 09, 2016: Carl Zeiss Meditec continues its growth trend 155
6.60 Dec 08, 2016: The Cooper Companies Announces Fourth Quarter and Full Year 2016 Results 156
6.61 Dec 07, 2016: Essilor Realigns its Organization with its Growing Businesses 157
6.62 Dec 07, 2016: VTI names executive director of manufacturing and engineering 158
6.63 Dec 07, 2016: Visioneering Technologies Announces Ms. Rosa Lee as New Executive Director of Manufacturing & Engineering 158
6.64 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 159
6.65 Nov 17, 2016: Former Valeant Executive And Former Philidor Ceo Charged In Manhattan Federal Court For Illegal Fraud And Kickback Scheme 160
6.66 Nov 10, 2016: Alcon introduces new AIR OPTIX plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting 161
6.67 Nov 09, 2016: New Study Shows Groundbreaking Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% Over Two Years 162
6.68 Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear 164
6.69 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 165
6.70 Oct 28, 2016: Hoya Reports Second Quarter Results 168
6.71 Oct 27, 2016: VTI Introduces the NaturalVue Multifocal QuickStart Calculator 169
6.72 Oct 26, 2016: Edmund Optics and Varioptic Announce the Availability of the Variable Focus Arctic Liquid Lens in the EO Catalog 169
6.73 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 170
6.74 Oct 21, 2016: Essilor: Nine-Month Consolidated Revenue up 7.8% at Constant Exchange Rates 177
6.75 Oct 13, 2016: Carl Zeiss Meditec appoints Steven C. Schallhorn, MD as Chief Medical Officer 179
6.76 Oct 12, 2016: Bausch + Lomb Booth to Feature Wet Lab During the Annual Meeting of the American Academy of Ophthalmology in Chicago 180
6.77 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 182
6.78 Sep 01, 2016: The Cooper Companies CFO Gregory W. Matz to Retire; Albert G. White Named Successor in Planned Transition 183
6.79 Sep 01, 2016: The Cooper Companies Announces Third Quarter 2016 Results 184
6.80 Aug 29, 2016: Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model 184
6.81 Aug 29, 2016: Drug Dispensing Contact lens Effectively Lowers Eye Pressure in Pre clinical Glaucoma Model 186
6.82 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 187
6.83 Aug 15, 2016: CooperVision Unveils Avaira Vitality Sphere and Toric Two-Week Contact Lenses 188
6.84 Aug 12, 2016: Carl Zeiss Meditec Grows in Ophthalmology and Microsurgery 189
6.85 Aug 11, 2016: Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results 190
6.86 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 190
6.87 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 190
6.88 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 192
6.89 Aug 01, 2016: Essilor International: Improving Lives by Improving Sight 194
6.90 Jul 29, 2016: Essilor - First-Half 2016 Results: Revenue Up 8.1% Excluding the Currency Effect 195
6.91 Jul 29, 2016: Hoya Reports First Quarter Financial Results 199
6.92 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 199
6.93 Jul 27, 2016: Carl Zeiss Meditec Recruits James V. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization 200
7 Appendix 201
7.1 Methodology 201
7.2 About GlobalData 204
7.3 Contact Us 204
7.4 Disclaimer 204
1.1 List of Tables
Table 1: Contact Lenses - Pipeline Products by Stage of Development 13
Table 2: Contact Lenses - Pipeline Products by Segment 14
Table 3: Contact Lenses - Pipeline Products by Territory 15
Table 4: Contact Lenses - Pipeline Products by Regulatory Path 16
Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date 17
Table 6: Contact Lenses - Ongoing Clinical Trials 18
Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development 19
Table 8: Contact Lenses - Pipeline Products by Stage of Development 21
Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
Table 10: Biolens - Product Status 23
Table 11: Biolens - Product Description 23
Table 12: Contact Lens - Product Status 24
Table 13: Contact Lens - Product Description 24
Table 14: Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 25
Table 15: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status 25
Table 16: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description 26
Table 17: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Status 26
Table 18: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Description 26
Table 19: Dailies Total 1 Colors SiHy Lens - Product Status 27
Table 20: Dailies Total 1 Colors SiHy Lens - Product Description 27
Table 21: Dailies Total 1 Toric SiHy Lens - Product Status 27
Table 22: Dailies Total 1 Toric SiHy Lens - Product Description 27
Table 23: Smart Contact Lens - Diabetes - Product Status 28
Table 24: Smart Contact Lens - Diabetes - Product Description 28
Table 25: Weekly WG SiHy Lens - Product Status 28
Table 26: Weekly WG SiHy Lens - Product Description 29
Table 27: Alcon Laboratories Inc - Ongoing Clinical Trials Overview 30
Table 28: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Clinical Assessment of a Regimen of AIR OPTIX plus HYDRAGLYDE Silicone Hydrogel Lenses and HYDRAGLYDE Containing Lens Care Solutions 31
Table 29: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 31
Table 30: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 32
Table 31: Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33
Table 32: Comfort Lens - Product Status 33
Table 33: Comfort Lens - Product Description 33
Table 34: Contact Lens - Glaucoma - Product Status 34
Table 35: Contact Lens - Glaucoma - Product Description 34
Table 36: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 35
Table 37: Smart Contact Lenses - Product Status 35
Table 38: Smart Contact Lenses - Product Description 35
Table 39: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 36
Table 40: MC - PHEMA Based Contact Lens - Product Status 36
Table 41: MC - PHEMA Based Contact Lens - Product Description 36
Table 42: Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 37
Table 43: Bionic Contact Lens - Product Status 37
Table 44: Bionic Contact Lens - Product Description 37
Table 45: Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 38
Table 46: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Status 38
Table 47: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Description 39
Table 48: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Status 39
Table 49: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Description 40
Table 50: Ultra Plus Powers Lens - Product Status 40
Table 51: Ultra Plus Powers Lens - Product Description 41
Table 52: Ultra Toric Lens - Product Status 41
Table 53: Ultra Toric Lens - Product Description 41
Table 54: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
Table 55: Contact Lens Drug Delivery Device - Product Status 42
Table 56: Contact Lens Drug Delivery Device - Product Description 42
Table 57: CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 43
Table 58: Biofinity Energys - Product Status 43
Table 59: Biofinity Energys - Product Description 43
Table 60: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status 44
Table 61: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description 44
Table 62: SiH Multifocal - Product Status 44
Table 63: SiH Multifocal - Product Description 45
Table 64: CooperVision Inc - Ongoing Clinical Trials Overview 46
Table 65: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses 47
Table 66: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial 47
Table 67: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
Table 68: EP Global Contact Lens - Product Status 48
Table 69: EP Global Contact Lens - Product Description 48
Table 70: Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 49
Table 71: Drug-Eluting Contact Lenses - Product Status 49
Table 72: Drug-Eluting Contact Lenses - Product Description 49
Table 73: e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
Table 74: Electronic Contact Lens - Product Status 50
Table 75: Electronic Contact Lens - Product Description 50
Table 76: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 51
Table 77: Drug Dispensing Contact Lens - Product Status 51
Table 78: Drug Dispensing Contact Lens - Product Description 51
Table 79: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 52
Table 80: Hyper-CL - Drug Delivery - Product Status 52
Table 81: Hyper-CL - Drug Delivery - Product Description 52
Table 82: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 53
Table 83: Contact Lens - Product Status 53
Table 84: Contact Lens - Product Description 53
Table 85: Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 54
Table 86: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 54
Table 87: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 54
Table 88: Anti-allergic Contact Lens - Product Status 55
Table 89: Anti-allergic Contact Lens - Product Description 55
Table 90: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 56
Table 91: Therapeutic Contact Lens - Product Status 56
Table 92: Therapeutic Contact Lens - Product Description 56
Table 93: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 57
Table 94: CLM041 - Product Status 57
Table 95: CLM041 - Product Description 57
Table 96: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
Table 97: Contact Lens - Dry Eye Disease - Product Status 58
Table 98: Contact Lens - Dry Eye Disease - Product Description 58
Table 99: Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
Table 100: Third PEG Hydrogel Contact Lens - Product Status 59
Table 101: Third PEG Hydrogel Contact Lens - Product Description 59
Table 102: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 60
Table 103: Presbia Flexivue Microlens - Product Status 60
Table 104: Presbia Flexivue Microlens - Product Description 60
Table 105: Presbia Plc - Ongoing Clinical Trials Overview 61
Table 106: Presbia Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 62
Table 107: RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview 63
Table 108: CLEAr Lens - Product Status 63
Table 109: CLEAr Lens - Product Description 63
Table 110: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 64
Table 111: Polymer Network Hydrogel Contact Lens - Product Status 64
Table 112: Polymer Network Hydrogel Contact Lens - Product Description 64
Table 113: SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview 65
Table 114: Duette Progressive With Tangible Hydra-PEG - Product Status 65
Table 115: Duette Progressive With Tangible Hydra-PEG - Product Description 65
Table 116: Duette With Tangible Hydra-PEG - Product Status 66
Table 117: Duette With Tangible Hydra-PEG - Product Description 66
Table 118: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 67
Table 119: Resonance Circuit Sensor Contact Lens - Product Status 67
Table 120: Resonance Circuit Sensor Contact Lens - Product Description 67
Table 121: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 68
Table 122: Stem Cell Contact Lens - Product Status 68
Table 123: Stem Cell Contact Lens - Product Description 68
Table 124: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 69
Table 125: Contact Lenses - Product Status 69
Table 126: Contact Lenses - Product Description 69
Table 127: University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 70
Table 128: Aerated Contact Lens - Product Status 70
Table 129: Aerated Contact Lens - Product Description 70
Table 130: Telescopic Contact Lens - Product Status 71
Table 131: Telescopic Contact Lens - Product Description 71
Table 132: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 72
Table 133: Vitamin E - Packed Lenses - Product Status 72
Table 134: Vitamin E - Packed Lenses - Product Description 72
Table 135: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 73
Table 136: Multifocal Contact Lens - Myopia - Product Status 73
Table 137: Multifocal Contact Lens - Myopia - Product Description 73
Table 138: Multifocal Contact Lens - Presbyopia - Product Status 74
Table 139: Multifocal Contact Lens - Presbyopia - Product Description 74
Table 140: University of Washington Pipeline Products & Ongoing Clinical Trials Overview 75
Table 141: Bionic Contact Lens - Product Status 75
Table 142: Bionic Contact Lens - Product Description 75
Table 143: Solar Powered Augmented Lenses - Product Status 76
Table 144: Solar Powered Augmented Lenses - Product Description 76
Table 145: Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 77
Table 146: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Status 78
Table 147: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Description 78
Table 148: BLC - 001: SVS - Product Status 78
Table 149: BLC - 001: SVS - Product Description 79
Table 150: BLC - 002: SVS - Product Status 79
Table 151: BLC - 002: SVS - Product Description 79
Table 152: BLC - 003: SVS/MF/fA - Product Status 80
Table 153: BLC - 003: SVS/MF/fA - Product Description 80
Table 154: BLC - 004: Toric - Product Status 80
Table 155: BLC - 004: Toric - Product Description 81
Table 156: BLC - 005: SVS/MF - Product Status 81
Table 157: BLC - 005: SVS/MF - Product Description 81
Table 158: BLC - 006: SVS - Product Status 82
Table 159: BLC - 006: SVS - Product Description 82
Table 160: BLC - 007: MF - Product Status 82
Table 161: BLC - 007: MF - Product Description 83
Table 162: BLC - 008: Astigmatism - Product Status 83
Table 163: BLC - 008: Astigmatism - Product Description 83
Table 164: BLC - 009: Astigmatism - Product Status 83
Table 165: BLC - 009: Astigmatism - Product Description 84
Table 166: XUV - 003: Aphakia - Product Status 84
Table 167: XUV - 003: Aphakia - Product Description 84
Table 168: XUV - 004: SVS - Product Status 84
Table 169: XUV - 004: SVS - Product Description 85
Table 170: XUV - 007: MF - Product Status 85
Table 171: XUV - 007: MF - Product Description 85
Table 172: XUV - 009: SVS - Product Status 86
Table 173: XUV - 009: SVS - Product Description 86
Table 174: XUV - 010: Astigmatism - Product Status 86
Table 175: XUV - 010: Astigmatism - Product Description 87
Table 176: XUV - 011: MF - Product Status 87
Table 177: XUV - 011: MF - Product Description 87
Table 178: XUV - 012: SVS - Product Status 87
Table 179: XUV - 012: SVS - Product Description 88
Table 180: XUV - 013: Astigmatism - Product Status 88
Table 181: XUV - 013: Astigmatism - Product Description 88
Table 182: XUV - 014: Presbyopia - Product Status 89
Table 183: XUV - 014: Presbyopia - Product Description 89
Table 184: XUV - 015: MF - Product Status 89
Table 185: XUV - 015: MF - Product Description 89
Table 186: Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90
Table 187: Contact Lens - Product Status 90
Table 188: Contact Lens - Product Description 90
Table 189: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Status 91
Table 190: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Description 91
Table 191: NaturalVue Toric 1 Day Contact Lenses - Product Status 91
Table 192: NaturalVue Toric 1 Day Contact Lenses - Product Description 92
Table 193: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status 92
Table 194: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description 92
Table 195: VTI MPC Lens - Product Status 93
Table 196: VTI MPC Lens - Product Description 93
Table 197: VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 94
Table 198: K-Lens - Product Status 94
Table 199: K-Lens - Product Description 94
Table 200: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 95
Table 201: TVT Device - Product Status 95
Table 202: TVT Device - Product Description 95
Table 203: Glossary 203
1.2 List of Figures
Figure 1: Contact Lenses - Pipeline Products by Stage of Development 13
Figure 2: Contact Lenses - Pipeline Products by Segment 14
Figure 3: Contact Lenses - Pipeline Products by Territory 15
Figure 4: Contact Lenses - Pipeline Products by Regulatory Path 16
Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date 17
Figure 6: Contact Lenses - Ongoing Clinical Trials 18
